Testing Alcohol Only Samples for Drugs and Drugs Only Samples for Alcohol
This study intends to supply information about the prevalence of psychoactive drugs and alcohol in suspected DUI samples which are suspected of only one of these rather than both drugs and alcohol.
Police samples for suspected DUI samples that have been sent for alcohol analysis or drug analysis only will be screened for drugs and alcohol respectively.
Driving Under the Influence
|Study Design:||Observational Model: Case-Crossover|
|Official Title:||Retrospective Study of Unrequested Analytical Data in DUID-cases From a 2 Week Period|
- assessment of both alcohol and drugs in suspected DUI cases [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
- prevalence of psychoactive substances in the general driving population [ Time Frame: three years ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||September 2008|
|Study Completion Date:||October 2011|
|Primary Completion Date:||September 2008 (Final data collection date for primary outcome measure)|
drivers of motorised vehicles suspected of driving under the influence of psychoactive drugs or alcohol
drivers stopped in police traffic controls and breathalysed positive for alcohol
There are 3 different possibilities for forensic analysis of suspected driving under the influence samples. Testing for alcohol or drugs only or testing for both alcohol and drugs.
Often if the primary suspicion of the apprehending police officer is of driving under the influence of drugs or alcohol then only laboratory analysis concerning that primary suspicion is requested.
The study aims to provide information about those 'missed cases' where only analysis for drugs or alcohol is carried out. Traffic police samples from a 2 week period are to be screened for both drugs and alcohol, even if the primary suspicion is only one of these.
The study is part of the EU-project DRUID. Altogether 13 European countries are participating in DRUID.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00648206
|National Public Health Institute|
|Principal Investigator:||Pirjo Lillsunde, Dr||National Public Health Institute, Helsinki, Finland|